Our product portfolio includes two additional products that will be used by patients in the home setting to manage pain after surgery. These products are in early stage development but also leverage the FDA's 505(b)(2) NDA regulatory pathway to develop proprietary innovations to FDA-approved, injectable drugs, which we refer to as branded reference drugs, that offer differentiated delivery modalities to improve patient quality of life and quality of care.
The global pain management therapeutics market has huge potential forgrowth due to the large population that is affected by medically significant pain. The market is growing at a moderate growth rate, driven by the cancer pain, low back pain and post-operative pain relief markets. In 2010, the global pain management therapeutics market was estimated at $28.6 billion, representing a CAGR of 5.3% between 2002 and 2010. The post-operative pain relief market, with sales of $6 billion in 2010, accounted for one fifth of the total pain management therapeutics market.
The PatchPump AHPA products are non-narcotic, pain relief products that are sterile, with prefilled labeled drug, single use, disposable and accurate for at home use.
The goal of the PatchPump AHPA products is to meet the changing pressures in the Hospital Healthcare system by increasing a hospital’s efficiency by reducing patient Length of Stay (LOS), reducing non– reimbursed operating expense and reducing the need for narcotic pain relief to improve the quality of pain management in the home setting.
This Product is being developed to deliver ketorolac, a non-steroidal anti-inflammatory drug (NSAID), subcutaneously by continuous infusion over a 2 – 5 day period to deliver short term relief of acute moderate to severe pain from a small, prefilled, sterile, labeled, PatchPump.
This Product is being developed to deliver a local anesthetic, bupivacaine, directly into the surgical wound area to provide up to 5 days of local pain relief from a small, prefilled, sterile, labeled, PatchPump.
The goal of these PatchPump at Home Patient Analgesia Products is to reduce patient length of stay in hospital, increase quality of hospital care, reduce hospital costs, reduce the need for oral narcotic therapy and improve pain management in the home setting.
SMT-201 and SMT-301 are development stage products that are not currently approved for sale by the US FDA.